MBOT Gains Visibility as LIBERTY Robotic System Draws Attention Ahead of Full Market Release

First-Time Appearance at Oppenheimer Conference Highlights Growing Market Interest

Microbot Medical Inc. (NASDAQ: MBOT) is stepping into the spotlight as it participates for the first time in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, scheduled for March 16-19, 2026. The company’s CEO, Harel Gadot, is set to present live on March 19, outlining not only the recent progress of the LIBERTY™ Endovascular Robotic System but also strategies projected to accelerate broader adoption across healthcare markets.

Milestones Set the Stage for Increased Shareholder Value

This invitation marks a notable milestone for Microbot Medical, reflecting both increased commercial momentum and new interest from leading institutions. The company has seen growing traction since the limited market release of its LIBERTY system in late 2025. Interest is expected to build toward the planned full market release at the Society of Interventional Radiology (SIR) conference in April 2026—events that may catalyze deeper adoption in the months ahead.

LIBERTY’s FDA clearance as the only single-use, remotely operated robotic system for peripheral endovascular procedures remains a differentiating advantage, aimed at enhancing both procedural precision and safety while addressing important unmet needs in the field.

Key Event Details and Strategic Outlook

LIBERTY Offers Differentiated Solution in Advanced Surgical Robotics

LIBERTY stands out as the only FDA cleared, single-use, remotely operated robotic platform for peripheral vascular navigation. Aimed at reducing radiation exposure and physical strain for physicians, LIBERTY’s limited market release has begun to generate meaningful interest from healthcare institutions. Microbot’s management positions the product as a new category in surgical robotics, emphasizing its potential to transform the landscape of endovascular care.

Current Trading Snapshot Reflects Momentum

Outlook: Strategic Developments Drive Both Opportunity and Uncertainty

As Microbot Medical prepares for major upcoming events, the combination of conference visibility, unique product positioning, and a ramp toward full-scale commercialization positions MBOT at a turning point. However, the company’s outlook is tempered by broader risks—including market conditions, regulatory uncertainties, and ongoing geopolitical factors as disclosed in recent filings with the SEC.

Key Takeaway

Microbot’s first-time participation at a major industry conference and the momentum surrounding LIBERTY’s limited market debut mark significant developments for MBOT investors and observers. With a full release on the horizon and management signaling both near-term strategy and long-term ambitions, market participants may want to follow the company's next moves, keeping an eye on both emerging opportunities and inherent risks.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI